论文部分内容阅读
目的探讨力达霉素经肝动脉介入治疗和静脉化疗两种给药途径对VX2兔肝癌的影响。方法开腹方法将VX2瘤组织块分别植入12只新西兰大白兔的肝左叶,建立VX2兔肝癌模型,B超检测肿瘤生长情况后随机分为两组:A组为力达霉素肝动脉介入组,B组为力达霉素静脉化疗组(6只/组)。A组在数字减影血管造影(DSA)引导下经肝固有动脉注入力达霉素(1 ml,0.05 mg/kg),B组通过耳缘静脉注入力达霉素(1 ml,0.05 mg/kg),给药10 d后活杀两组动物,取肝肿瘤组织4%多聚甲醛固定,免疫组化方法测定CD34、增殖细胞核抗原(PCNA)蛋白的表达;应用Cobas 8000检测血清生化丙氨酸转氨酶(ALT)和天冬氨酸转氨酶(AST)水平;计算并比较两种不同给药方式的肿瘤生长抑制效果。结果给药10 d后两组肿瘤均有增大,但与B组相比,A组肿瘤生长率明显降低(P<0.05);免疫组化结果显示,介入途径给药更能下调CD34、PCNA表达水平。结论在治疗兔肝癌VX2中,力达霉素经肝动脉介入给药治疗效果优于静脉化疗给药。
Objective To investigate the effect of lidamycin on hepatic carcinoma of VX2 rabbit by hepatic artery intervention and intravenous chemotherapy. Methods The VX2 tumor tissue pieces were implanted into the left lobe of the liver of 12 New Zealand white rabbits respectively. The model of VX2 rabbit liver cancer was established by laparotomy. The tumors were divided into two groups randomly. The group A was lentomycin hepatic artery Intervention group, B group for the lidamycin intravenous chemotherapy group (6 / group). Group A was injected with doxorubicin (1 ml, 0.05 mg / kg) via hepatic artery under the guidance of digital subtraction angiography (DSA), while group L was injected with lidamycin (1 ml, 0.05 mg / kg) .After 10 days of treatment, the animals in both groups were sacrificed and killed. The tumor tissues were fixed with 4% paraformaldehyde and the expressions of CD34 and proliferating cell nuclear antigen (PCNA) were detected by immunohistochemistry. Cobas 8000 was used to detect serum biochemical amylase Acid aminotransferase (ALT) and aspartate aminotransferase (AST) levels; calculated and compared two different modes of administration of tumor growth inhibitory effect. Results The tumors in both groups increased after 10 d administration, but the tumor growth rate in group A was significantly lower than that in group B (P <0.05). The results of immunohistochemistry showed that the interventions could decrease the expression of CD34, PCNA The expression level. Conclusion In the treatment of rabbit liver cancer VX2, levomycin is superior to intravenous chemotherapy by hepatic artery intervention.